Medical executive Robert Hindes, MD, serves as the chief medical officer of Trek Therapeutics (TREKtx), a public benefit corporation dedicated to developing highly effective accessible and affordable treatments for infectious diseases. Prior to forming Trek, Robert Hindes, MD, and his fellow cofounders had helped develop seven approved antiviral drugs.
In October of 2015, TREKtx and Theravance Biopharma announced they are engaging in a Phase 2a trial of TD-6450, an NS5A inhibitor used to treat individuals with HCV. Patients will receive TD-6450 in combination with the HCV protease inhibitor faldaprevir (FDV), another compound in the portfolio of TREKtx, and ribavarin (RBV). Conducted in the United States, the Phase 2a trial will involve individuals with HCV genotype 4. If the study demonstrates safety and efficacy, TREKtx hopes to begin trials in Egypt to address the urgent need for HCV antivirals. Egypt has a higher prevalence of chronic HCV than any other country globally.
One of the most common chronic infectious diseases in the United States, the active hepatitis C virus (HCV) affects between 2.7 and 3.5 million individuals in the US, and 170 million worldwide. HCV is the most common cause of such liver conditions as cancer and cirrhosis and stands as the leading cause of liver transplantation.
In October of 2015, TREKtx and Theravance Biopharma announced they are engaging in a Phase 2a trial of TD-6450, an NS5A inhibitor used to treat individuals with HCV. Patients will receive TD-6450 in combination with the HCV protease inhibitor faldaprevir (FDV), another compound in the portfolio of TREKtx, and ribavarin (RBV). Conducted in the United States, the Phase 2a trial will involve individuals with HCV genotype 4. If the study demonstrates safety and efficacy, TREKtx hopes to begin trials in Egypt to address the urgent need for HCV antivirals. Egypt has a higher prevalence of chronic HCV than any other country globally.
One of the most common chronic infectious diseases in the United States, the active hepatitis C virus (HCV) affects between 2.7 and 3.5 million individuals in the US, and 170 million worldwide. HCV is the most common cause of such liver conditions as cancer and cirrhosis and stands as the leading cause of liver transplantation.